# Interim Report H1 2019/20

### Growth and stable earnings

30 October 2019




### Highlights Q2 2019/20

- ✓ Topline growth of 5.8%
- ✓ LFL growth of 0.3%
- ✓ Stable earnings at DKK 107.4 m (Q2 2018/19: DKK 108.6 m)
- ✓ Gross margin stable at 44.7% including normalisation from Kosmolet (Q2 2018/19: 44.9%)
- ✓ 6 consecutive quarters with **matas.dk growing 50%** or more
- ✓ Rollout plan for new store concept 'Matas Life' based on test results
- ✓ Narrowed range for 2019/20 guidance for topline and LFL, lower CAPEX guidance



\* EBITDA before exceptional items and before effects of IFRS 16

# Overview: Q2 2019/20 vs. Q2 2018/19





\* Before effect from IFRS 16.

# Revenue development by category: Q2 2019/20 vs. Q2 2018/19

Revenue DKK million	2019/20 Q2	2018/19 Q2	Growth Q2 vs Q2
High-End Beauty	278	264	5.0%
Mass Beauty	268	263	2.0%
Vital	136	105	29.6%
Material	82	86	-4.1%
MediCare	48	47	2.5%
Other	3	3	-18.2%
Total retail sales (own store and webshops)	815	768	6.1%
Wholesale sales etc. (incl. Kosmolet)	8	9	-16.2%
Total revenue	823	777	5.8%

#### Distribution of retail sales revenues Q2 2019/20





\* Before effect from IFRS 16.

# Cash flow, working capital and inventories

# Cash flow and working capital developments


- Cash generated from operations, including changes to working capital, increased DKK 16 m
- CAPEX increased DKK 3 m due to investments in Matas Life, a new webshop warehouse and online investments
- As a result, Free cash flow rose DKK 7 m to DKK 6 m

#### Inventories

• Approximately DKK 75 m in inventory increase from Firtal, Kosmolet and new webshop in Humlebæk compared to end-Q2 2018/19

	Q2 2019/20	Q2 2019/20	Q2 2018/19	Change
DKK million	Post IFRS 16	Pre IFRS 16	Pre IFRS 16	ΥοΥ
Cash from operations*	109.0	62.8	46.6	16.2
Paid interest and taxes	-5.6	-5.6	-4.6	-1.0
Cash flow from operating act.	103.4	57.2	42.0	15.2
CAPEX	-39.1	-39.1	-36.2	-2.9
Acquisitions of securities/ inv.	-5.4	-5.4	0.0	-5.4
Cash flow from investing act.	-44.5	-44.5	-36.2	-8.3
Free cash flow	58.9	12.7	5.8	6.9

\* Including changes to working capital.



# Strategic progress in Q2 2019/20

Live our purpose Beauty & Wellbeing for life

 $\left( 2 \right)$ 

(3)

(5)

**Win online** From top 3 to undisputed market leader

**Reignite store growth** Renew & consolidate store footprint

Open new growth paths New revenue streams

Change how we work Cost savings & efficiency gains



# Win online 2023 ambition: From top 3 to undisputed market leader

Step 1: Fuelling matas.dk and Matas' market leading omnichannel proposition

- ✓ No. 1 in Beauty & Wellbeing
- ✓ 54% growth on matas.dk in 2018/19
- ✓ 59% growth on matas.dk in H1 2019/20
- ✓ Significantly outgrowing market pace of ~20-25% growth

### Step 2: Acquisition of Firtal completed

- $\checkmark\,$  Performance as expected in investment case
- $\checkmark\,$  Synergies realisation on track
- ✓ No. 1 in Vital space

### Next phase: We aim for undisputed market leadership

- > Increased investments in organic growth in both Matas and Firtal
- > Potentially bolt on acquisitions of limited size and with short term payback
- > Higher CAPEX allocation than expected

mata

# Reignite store growth: Renew & consolidate store footprint

#### First evaluation of Matas Life test rollout

#### Matas Life test stores

- ✓ 10 Matas Life test stores opened from March to July
- ✓ Five additional stores opened in October

#### **Evaluation on three parameters**

- Customer response (qualitative and quantitative)
- Footprint and market assessment
- Financials

### Renew & consolidate store footprint

Initial conclusions

#### Store mergers, relocations and expansion

- Solid financials from full Matas Life openings
- Landlord co-financing required
- Increased consolidation is a priority
- => CAPEX allocation as expected


#### 1:1 store upgrades

- Good case in specific store types and locations
- Landlord co-financing required
- Continuous facelift/maintenance at lower CAPEX
  per store
- => Lower CAPEX allocation than expected

Seven additional Matas Life stores planned for Q3 2019/20 and up to 10 stores in Q4 2019/20

Interim Report H1 2019/20

matas



#### **Cost drivers**

- Cost efficiency actions completed, securing underlying cost lower in Q2 2019/20 than in Q2 2018/19
- Added cost from Firtal and Kosmolet
- Continued fuelling of matas.dk
- Cost inflation

#### Q2 2019/20

Permanent reductions in underlying cost base compared to Q2 2018/19

Efficiency in

- store to reflect LFL development
- HQ via process optimisation + work smarter •

#### H2 2019/20

Positive effects will continue in H2 2019/20

Cost efficiency actions will have an EBITDA effect on FY 2019/20 approximately DKK 25 m

#### Interim Report H1 2019/20

10

### Financial targets for 2019/20

- Overall revenue growth of 3.5 5.5%
- Underlying (like-for-like) revenue growth of 0.5 1.5%
- EBITDA\* margin before special items of 14 15%
- CAPEX of DKK 150 170 m

(previously 3.5 – 6.5%)

(previously 0.5 – 2.5%)

(unchanged)

(previously DKK 200 - 220 m)

The financial targets are presented inclusive of the full-year effects of Firtal and Kosmolet.

The financial targets for 2019/20 is based on assumptions of slightly growing customer demand for beauty, health and personal care products, a continuing decline in physical store footfall and persistently intensive competition in the beauty, health and personal care market.

\* Before effects of IFRS 16

Interim Report H1 2019/20

mata





# matas

### The Matas Group – the No 1 Danish Health & Beauty retailer



Numbers for Q2 2019/20 or end-Q2 2019/20 unless stated otherwise.

\* Includes one store in Greenland. \*\* Includes revenue from Firtal for the period 13 November 2018 to 30 September 2019 and revenue from Kosmolet from 11 June to 30 September 2019.

# Key figures for Q2 2019/20

#### Comments

- 5.8% revenue growth
  - **Beauty** (66.3% of total sales) increased 3.5%
    - High-end beauty (33.7% of total sales) increased 5.0%
    - Mass beauty (32.6% of total sales) increased 2.0%
  - Vital increased 29.6%
  - Material decreased 4.1%
  - Medicare increased 2.5%
  - Other and Wholesale etc.
    decreased
- Gross profit increased DKK 8 m or 2.4%, driven by higher sales

DKK million	Q1 2019/20 Post IFRS 16	Q2 2019/20 Pre IFRS 16	Q2 2018/19 Pre IFRS 16	Growth YoY
Revenue	822.5	822.5	777.2	5.8%
Gross profit	357.5	357.5	349.0	2.4%
Other external costs	39.9	86.1	84.6	1.8%
Staff costs	178.6	178.6	165.3	8.0%
EBITDA	139.0	92.8	99.1	-6.4%
Amortisation and depreciation	93.3	46.3	43.2	7.2%
Operating profit (EBIT)	45.7	46.5	55.9	-16.8%
Net financials	-10.2	-6.4	-5.0	28.0%
Profit before tax	35.5	40.1	50.9	-21.2%
Tax on profit for the period	9.5	9.5	14.3	-33.6%
Profit for the period	26.0	30.6	36.6	-16.4%
Special items	14.6	14.6	9.5	
EBITDA before special items	153.6	107.4	108.6	-1.1%
Adjusted net profit	56.1	60.7	61.0	-0.4%
Gross margin	43.5%	43.5%	44.9%	
EBITDA margin	16.9%	11.3%	12.8%	
EBITDA margin before special items	18.7%	13.1%	14.0%	
Diluted earnings per share, DKK	0.68	0.80	0.97	-17.9%
Tax rate	26.7%	23.7%	<b>28</b> .1%	

matas

14

# Quarterly income statement for 2018/19 and 2019/20

	2019/20 Post IFRS 16	2019/20 Pre IFRS 16	2019/20	2018/19	2018/19	2018/19	Growth Pre IFRS 16
DKK million	Q2	Q2	Q1	Q4	Q3	Q2	Q2 vs Q2
Revenue	823	823	876	828	1,093	777	5.8%
Gross profit	358	358	394	377	481	349	2.4%
Gross margin	43.5%	43.5%	<b>45.0</b> %	45.6%	44.0%	<b>44.9</b> %	
Other external costs	40	86	94	101	96	85	1.8%
Staff costs	179	179	183	184	180	165	8.0%
EBITDA	139	93	117	93	205	99	-6.4%
Amortisation and depreciation	93	46	44	43	42	43	7.2%%
Operating profit	46	47	73	49	163	56	-16.8%
Net financials	10	6	6	6	6	5	28.0%
Profit before tax	36	40	67	43	157	51	-21.2%
Tax on profit for the period	10	10	15	10	35	14	-33.6%
Profit for the period	26	31	52	33	122	37	-16.4%
Diluted Earnings per share, DKK	0.68	0.80	1.36	0.87	3.21	0.97	-17.9%
EBITDA margin	16.9%	11.3%	13.4%	11.2%	18.7%	12.8%	
Special items	15	15	3	3	1	9	
EBITDA before special items	154	107	120	96	206	109	
EBITDA margin before special items	18.7%	13.1%	13.7%	11.6%	18.8%	14.0%	
Tax rate	24.7%	23.7%	22.5%	23.1%	22.0%	28.1%	
Adjusted net profit	56	61	72	53	140	61	-0.4%
							mat

Interim Report H1 2019/20 15

# Strong online growth continues in Q2 2019/20

Q2 ONLINE REVI	ENUE $^{*}$ IN $\%$ OF TOTAL REVENUE	Online revenue* (% of total revenue)	Q2 2019/20	Q2 2018/19	YoY growth
12.0%	IN Q2 2019/20	matas.dk	6.5%	4.6%	53%
A 107		Firtal	5.5%	-	-
4.6%	IN Q2 2018/19	Matas Group	12.0%	4.6%	180%

MATAS.DK IN G	2 2019/20
53%	GROWTH FROM Q2 2018/19
6.5%	OF TOTAL REVENUE

Online revenue* (% of total revenue)	Q1 2019/20	Q1 2018/19	YoY growth
matas.dk	5.9%	3.7%	67%
Firtal	5.0%	-	-
Matas Group	10.9%	3.7%	207%

Online revenue* (% of total revenue)	H1 2019/20	H1 2018/19	YoY growth
matas.dk	6.3%	4.1%	59%
Firtal	5.2%	-	-
Matas Group	11.5%	4.1%	1 <b>92</b> %

matas

16

# Underlying revenue (like for like) calculations

#### Like for like assumptions

- A store is part of the LFL calculation after 13 months
- matas.dk is counted as one store in LFL
- New stores are included in LFL after 13 months
- Firtal will be included in LFL from December 2019 (4 months of 2019/20)
- Kosmolet A/S will not be included in LFL in 2019/20

	Q2 2019/20	Q2 2018/19
Revenue growth	5.8%	-1.6%
Underlying revenue growth (LFL)	0.3%	-1.9%
Stores in LFL calculation* (#)	268	270
Stores in total* (#)	275	278

\* Number of stores end of period incl. matas.dk. Excluding Firtal Group.



# Cost development in Q2 2019/20

#### Other external costs pre IFRS 16 up DKK 2 m YoY:

- Non-recurring costs fell DKK 9 m compared to 18/19
  - For 2018/19 9 m were related to the acquisition of Firtal Group
- DKK 13 m due to new Operating costs from Firtal Group and Kosmolet
- DKK 3 m down driven by cost effeiciency actions

#### Staff costs up DKK 13 m YoY:

- Non-recurring costs rose DKK 3 m compared to 18/19
  - For 2019/20, DKK 3 m were related to executive changes in Matas
- DKK 10 m increase in Staff costs from matas.dk, Firtal and Kosmolet

	Q2 2019/20 Post IFRS 16	Q2 2019/20 Pre IFRS 16	Q2 2018/19 Pre IFRS 16	Growth YoY
Other external costs (OEC)	39.9	86.1	84.6	1.8%
Non-recurring OEC	0.9	0.9	9.5	1.0/0
OEC as a percentage of revenue	4.9%	10.5%	10,9%	
Staff costs	178.6	178.6	165.3	8.0%
Non-recurring staff costs	3.3	3.3	0.0	
Staff costs as a percentage of revenue	21.7%	21.7%	21.3%	
Total costs	218.5	264.7	249.9	5.9%



# IFRS 16 Leasing effects on Q2 2019/20

- Matas has implemented IFRS 16 Leasing with effect from 1 April 2019.
- IFRS 16 primarily impacts the balance sheet due to store leases previously being classified as operational leases and hence not included in Matas' balance sheet.
- EBITDA, EBIT, EBT and cash flow are impacted.
  - EBITDA is positively affected as leasing costs from operating leases now are recognized as depreciation and interest costs rather than previously as leasing costs relating to rent under Other external costs.
  - EBIT is marginally affected as a result of increased depreciations.
  - Free cash flows are improved due to the increase in operating activities.
  - Total cash flow are unchanged, however the increase in cash flow from operating activities is offset by a corresponding negative impact from cash flow from financing activities.

DKK million	Q2 2019/20	Q2 2019/20	Q2 2018/19
	Post IFRS 16	Pre IFRS 16	Pre IFRS 16
EBITDA	139	93	99
EBITDA before exceptional items	154	107	109
Amortisation, depreciation, imp.	-93	-46	-43
EBIT	46	47	56
Financial items, net	-10	-6	-5
Profit before tax	36	40	51
EBITDA margin before exceptional items	18.7%	13.1%	14.0%
Free cash flow	59	13	6
Lease assets (right of use assets)	849	0	0
Total property, plant and equipment	1,096	224	189
Total assets	6,537	5,665	5,256
Total equity	2,640	2,651	2,494
Lease liability (non-current and current)	855	0	0
Total liabilities	3,897	2,762	2.762
Total equity and liabilities	6,537	5,665	5,256
Net interest-bearing debt	2,592	1,737	1,637
			mat

Interim Report H1 2019/20

### What do Matas' customers buy

#### MATAS CATEGORIES BEAUTY

Everyday (mass) and luxury (high end) beauty products and personal care, including cosmetics, fragrances, skincare and haircare products.

#### VITAL

Vitamins, minerals, supplements, specialty foods and herbal medicinal products.


#### MATERIAL

Household and personal care products, including household cleaning and maintenance products, babycare, footcare and sports-related products.

#### **MEDICARE**

OTC medicine, nursing products, etc.

#### Q2 2019/20 distribution of turnover by category



#### PEERS BY CATEGORY BEAUTY

Supermarkets & hypermarkets Discounters and parallel import Department stores Tax free Perfumeries Online

#### VITAL

Specialist Health stores Pharmacies Supermarkets Online

#### MATERIAL

Supermarkets & hypermarkets Pharmacies Discounters and parallel import

MEDICARE Pharmacies Supermarkets & hypermarkets

Interim Report H1 2019/20


matas

# Revenue development by category

	2019/20	2019/20	2018/19	2018/19	2018/19	2018/19	Growth
DKK million	Q2	Q1	Q4	Q3	Q2	Q1	Q2 vs Q2
High-End Beauty	278	313	288	483	264	297	5.0%
Mass Beauty	268	297	267	337	263	301	2.0%
Vital	136	131	140	132	105	98	29.6%
Material	82	80	69	82	86	89	-4.1%
MediCare	48	46	46	47	47	46	2.5%
Other	3	2	10	6	3	3	-18.2%
Total retail sales (own store and webshops)	815	869	820	1.087	768	834	6.1%
Wholesale sales etc. (incl. Kosmolet)	8	7	8	6	9	10	-16.2%
Total revenue	823	876	828	1.093	777	844	5.8%

# Trading days 2016/17 to 2019/20

Q1 Q2 Q3 Q4







Team



**Gregers** Wedell-Wedellsborg **CEO** gww@matas.dk +45 4816 5555



Anders Skole-Sørensen CFO as@matas.dk +45 4816 5555



Elisabeth Toftmann Klintholm Head of IR & Corporate Affairs etk@matas.dk +45 4816 5548



### Forward Looking Statements

This presentation contains statements relating to the future, including statements regarding Matas A/S' future operating results, financial position, cash flows, business strategy and plans for the future. The statements can be identified by the use of words such as "believes", "expects", "estimates", "projects", "plans", "anticipates", "continues" and "intends" or any variations of such words or other words with similar meaning. The statements are based on management's reasonable expectations and forecasts at the time of the disclosure of the interim report. Any such statements are subject to risks and uncertainties and a number of different factors, of which many are beyond Matas A/S' control, can mean that the actual development and the actual result will differ significantly from the expectations contained in the interim report. Without being exhaustive, such factors include general economics and commercial factors, including market and competitive matters, supplier issues and financial issues.

